ROTH Capital Partners Acts as Sole Manager &
Sole Placement Agent for Altimmune, Inc. (Nasdaq: ALT)
in its $41.9 Million in Funding


For more information please contact:

Investment Banking
James Antonopoulos
Managing Director
Co-Head of Healthcare
Investment Banking
(646) 358-1906

Eric B. Cheng
Managing Director
Co-Head of Healthcare
Investment Banking
(646) 358-1901
Equity Capital Markets
Aaron Gurewitz
Head of Equity
Capital Markets
(949) 720-5703
Nazan Akdeniz
Senior Vice President
(949) 720-5740
Lou Ellis
Senior Vice President
(949) 720-5739


Transaction Information
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, has closed a registered direct offering of common units and pre-funded units for gross proceeds of approximately $25 million. Together with Altimmune’s registered direct offering announced on September 24 and follow-on offering announced September 28, the company received aggregate gross proceeds of $41.9 million.

"We are pleased with the outcome of our fundraising efforts,” said William J. Enright, President and Chief Executive Officer of Altimmune. “These proceeds strengthen our balance sheet and position us well as we continue the development of NasoVax and our other product candidates.”

Altimmune intends to use the proceeds from these offerings for the continued advancement of development activities for the Company’s clinical-stage product pipeline, general corporate purposes, strategic growth opportunities and repayment of the Company’s outstanding $1.5 million in aggregate principal amount of convertible notes.

ROTH Capital Partners acted as sole manager for the underwritten public offering and sole placement agent for both registered direct offerings.

About Altimmune, Inc.
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of infectious disease. NasoVAX our influenza vaccine candidate has unique characteristics, stimulating multiple arms of the immune system that offer the potential to stop infection and the spread of flu, while being easier to administer through an intranasal spray. NasoShield is a next-generation anthrax vaccine candidate that is intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines. For more information, please visit
(Source: Company Press Release | 10/3/18)

About ROTH Capital Partners
ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S. For more information on ROTH, please visit

Date of Announcement: 10/11/18

The material, information and  facts discussed in this announcement other than the information regarding ROTH Capital Partners, LLC ("ROTH") and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of ROTH. Copyright 2018.